Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

G. Giaccone, E.F. Smit, M. de Jonge, E Dansin, E Briasoulis, A. Ardizzoni, JY Douillard, D Spaeth, D Lacombe, B Baron, P Bachmann, P Fumoleau

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)667-72
JournalEuropean Journal of Cancer
Issue number5
Publication statusPublished - 2004

Cite this